Dr. Reddy's & Gilead partner for global HIV drug access

Dr. Reddy’s Laboratories (NYSE:RDY) has signed a voluntary licensing agreement with Gilead Sciences Ireland UC, allowing it to manufacture and commercialize Lenacapavir in India and 120 other countries.

Lenacapavir, approved by the USFDA for treating multi-drug resistant HIV-1 in heavily treatment-experienced adults, is also under investigation for potential use in HIV prevention.

"Lenacapavir marks an important milestone for Dr. Reddy’s in patient access and affordability for pre and post-exposure treatment of HIV. The collaboration with Gilead will help us make this latest treatment option available to patients in 120 primarily low- and lower- middle income countries, including in India," said Deepak Sapra, CEO-API & Services, Dr. Reddy’s Laboratories.

The agreement aims to address high disease burdens in low- and middle-income countries.

Following the announcement, Dr. Reddy’s Laboratories share price held steady at $79.56.